Thymosin Beta-4 (Tβ4)
43-Amino Acid Regenerative Peptide · Tissue Repair & Healing
Overview
Naturally occurring 43-amino acid peptide crucial for tissue repair, wound healing, and cellular regeneration. Promotes angiogenesis, reduces inflammation, and supports cell migration and differentiation.
Direct systemic delivery provides optimal bioavailability and distribution to target tissues for comprehensive regenerative effects including angiogenesis, cell migration, and differentiation.
Clinical trials show 67% complete healing versus 25% placebo in pressure ulcers.
Enhanced tissue regeneration and reduced healing time in surgical wounds.
Accelerated recovery in muscle, tendon, and ligament injuries.
Phase 2b trials show 43% reduction in infarct size when given within 6 hours.
Mechanism
Naturally occurring 43-amino acid peptide crucial for tissue repair, wound healing, and cellular regeneration. Promotes angiogenesis, reduces inflammation, and supports cell migration and differentiation.
Direct systemic delivery provides optimal bioavailability and distribution to target tissues for comprehensive regenerative effects including angiogenesis, cell migration, and differentiation.
Clinical trials show 67% complete healing versus 25% placebo in pressure ulcers.
Research areas
- Naturally occurring 43-amino acid peptide crucial for tissue repair, wound healing, and cellular regeneration. Promotes angiogenesis, reduces inflammation, and supports cell migration and differentiation.
- Direct systemic delivery provides optimal bioavailability and distribution to target tissues for comprehensive regenerative effects including angiogenesis, cell migration, and differentiation.
- Clinical trials show 67% complete healing versus 25% placebo in pressure ulcers.
- Enhanced tissue regeneration and reduced healing time in surgical wounds.
- Accelerated recovery in muscle, tendon, and ligament injuries.
- Phase 2b trials show 43% reduction in infarct size when given within 6 hours.
- Improved neurological outcomes and functional recovery in animal models.
Research notes
- Mild injection site reactions
- Local inflammation at injection sites
- Severe injection site reactions or persistent inflammation
- Signs of systemic allergic reaction (rash, breathing difficulty)
- Unexpected cardiovascular symptoms during treatment
- Any signs of infection at injection sites
- Active chemotherapy treatment
- Severe systemic allergies to peptides
- Thymosin Beta-4 eye drops (0.1% RGN-259) showed Phase 2 efficacy for severe dry eye with significant symptom improvements lasting 28 days post-treatment. Phase 3 trials for neurotrophic keratopathy demonstrated corneal healing and comfort improvements, indicating efficacy beyond general wound healing.
Pharmacokinetics
- Direct systemic delivery provides optimal bioavailability and distribution to target tissues for comprehensive regenerative effects including angiogenesis, cell migration, and differentiation.
FAQs
Can Thymosin Beta-4 help with muscle recovery after surgery?
Yes, clinical trials showed Thymosin Beta-4 accelerates post-surgical wound healing by approximately one month in pressure and venous ulcers. This healing acceleration extends to post-surgical tissue repair, making it relevant for accelerating recovery from surgical trauma and improving biomechanical tissue properties.
Why use Thymosin Beta-4 instead of the TB-500 fragment for healing?
Thymosin Beta-4 (full 43 amino acids) provides comprehensive regenerative effects with proven clinical efficacy. TB-500 (7-amino-acid fragment) is more economical and stable. Full-length offers more robust Phase 2 clinical data; fragment offers cost efficiency - both work, choose based on budget and evidence requirements.
Can Thymosin Beta-4 improve cardiac function after a heart attack?
Phase 2b trials showed 43% reduction in heart attack infarct size when Thymosin Beta-4 was administered within 6 hours. It promotes cardiomyocyte migration and survival while stimulating coronary vasculogenesis, indicating potential for cardiac protection, though larger trials are needed for clinical approval.